09.01.2024 - Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., . Seite 1
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesThe clinical study, COVALENT-112, has initiated.
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended moving on from Tidewater Inc. (NYSE: TDW). "It’s moved too much," he added.
Biomea Fusion, Inc (NASDAQ:BMEA) Short Interest Up 23 5% in December kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.